Fig. 7: CMTM6 sensitizes HCC to Dox and its downregulation predicts poor prognosis of TACE treatment outcome. | Cell Death & Disease

Fig. 7: CMTM6 sensitizes HCC to Dox and its downregulation predicts poor prognosis of TACE treatment outcome.

From: CMTM6 inhibits tumor growth and reverses chemoresistance by preventing ubiquitination of p21 in hepatocellular carcinoma

Fig. 7

A GSEA plot showing that CMTM6 expression is negatively correlated with DNA repair in HCC. B The indicated cells were treated with 0.2 μM Dox for 0, 8 or 16 h. Cell lysates were then extracted and subjected to Western blot analysis. C HuH-7 and D HepG2 cells transfected with the indicated constructs were treated with Dox at different concentrations for 48 h and cell viability was then measured by the CCK-8 assay. E HuH-7 and F HepG2 cells transfected with the indicated constructs were treated with 0.2 μM Dox for different time periods and cell viability was measured by the CCK-8 assay. G HuH-7 (top) and HepG2 (bottom) cells transfected with the indicated constructs were treated with 0.5 μM Dox for 48 h and cell apoptosis was assessed by flow cytometric analysis. H Kaplan–Meier analysis of OS after the first TACE treatment according to CMTM6 expression status. I Multivariate analysis of CMTM6 expression and clinical variables in HCC patients who received TACE treatment. The experiments were performed in triplicate. The error bars represent the mean ± SD. **P < 0.01; ***P < 0.001; ****P < 0.0001.

Back to article page